Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Apple’s iPhone Sales Decline – $AAPL $DIA $INVO

By John F. Heerdink, Jr.

Reportedly, Apple (AAPL) first-quarter earnings dropped, missing estimates as iPhone sales disappoint. The company faced significant headwinds throughout November and December, from COVID lockdowns and worker protests at manufacturer Foxconn’s facility in Zhengzhou, China. The plant, which employs 200,000 workers, produces the bulk of Apple’s iPhone 14 Pro and iPhone 14 Pro Max handsets.

Earning Highlights:

  • Revenue stood at $117.1 billion versus $121.1 billion expected.

  • Adjusted earnings per share was $1.88 versus $1.94 estimated.

  • iPhone generated revenue of $65.7 billion versus $68.3 billion expected.

  • Mac reported revenue of $7.7 billion versus $9.72 billion expected.

  • iPad revenue stood at $9.4 billion versus $7.7 billion estimated.

  • Wearables contributed $13.4 billion lower than $15.3 billion expected.

  • Services unit generated $20.7 billion versus $20.4 billion expected.

“As we all continue to navigate a challenging environment, we are proud to have our best lineup of products and services ever, and as always, we remain focused on the long term and are leading with our values in everything we do,” stated Apple CEO Tim Cook.

Dow 30 component Apple (AAPL) revolutionized personal technology with the introduction of the Macintosh in 1984. Today Apple leads the world in innovation with iPhone, iPad, Mac, Apple Watch, and Apple TV. Apple’s four software platforms — iOS, macOS, watchOS, and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay, and iCloud. Apple’s more than 100,000 employees are dedicated to making the best products on earth, and to “leaving the world better than they found it. To learn more about Apple (AAPL) and track its ongoing progress at Vista Partners Apple (AAPL), Coverage Page.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

(Read Original Story: Apple misses Q1 earnings expectations as iPhone sales fall short in Yahoo Finance )


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us